SEC Company Response from Can-Fite BioPharma Ltd. (CANF) (CIK 0001536196) (CANF) — Apr 6, 2020
Can-Fite BioPharma Ltd. (CANF) (CIK 0001536196)
Date: April 6, 2020 · CIK: 0001536196 · Accession: 0001213900-20-008638
AI Filing Summary & Sentiment
File numbers found in text: 333-237443
Show Raw Text
CORRESP
1
filename1.htm
Can-Fite BioPharma Ltd.
10 Bareket
Street
Kiryat Matalon,
P.O. Box 7537
Petach-Tikva
4951778, Israel
April 6, 2020
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Re:
Can-Fite BioPharma Ltd.
Registration Statement on Form F-1
File No. 333-237443
VIA EDGAR
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act
of 1933, as amended, Can-Fite BioPharma Ltd. (the “Company”) hereby respectfully requests that the effectiveness
of the Registration Statement on Form F-1 (File No. 333-237443) of the Company (the “Registration Statement”)
be accelerated so that the Company’s Registration Statement will become effective at 9:00 a.m., Eastern Time, on April 7,
2020 or as soon thereafter as may be practicable.
The undersigned respectfully requests that it
be notified of the effectiveness of the Registration Statement by telephone call to our counsel, McDermott Will & Emery LLP,
by calling Gary Emmanuel at (212) 547-5541. The Company hereby authorizes Mr. Emmanuel to orally modify or withdraw this request
for acceleration.
Very truly
yours,
CAN-FITE BIOPHARMA
LTD.
By: /s/ Pnina Fishman, Ph.D.
Name: Pnina Fishman, Ph.D.
Title: Chief Executive Officer
cc: Gary Emmanuel (McDermott Will & Emery LLP)